<DOC>
	<DOCNO>NCT00681031</DOCNO>
	<brief_summary>Primary objective : To demonstrate whether ZOSTAVAX® minimum release specification approach expiry potency elicits acceptable Varicella-Zoster Virus ( VZV ) antibody fold rise ( measure gpELISA ) pre-vaccination 4 week post-vaccination Secondary objective : To describe safety profile ZOSTAVAX® minimum release specification approach expiry potency</brief_summary>
	<brief_title>Zostavax® Minimum Release Specification Approaching Expiry</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<criteria>Subject either gender age ≥50 year Positive history varicella residence &gt; 30 year country endemic VZV infection All females must postmenopausal negative serum urine pregnancy test acceptable method birth control three month vaccination Subject sign informed consent form prior study procedure Subject febrile within 72 hour prior vaccination Subject prior history Herpes Zoster clinically diagnose physician Subject previously receive varicella zoster vaccine Exposure varicella herpeszoster within 4 week prior vaccination Subject receive live virus vaccine within 4 week prior vaccination , expect receive live virus vaccine study Subject receive inactivated vaccine within 2 week prior vaccination , expect receive inactivate vaccine study Subject treat immunoglobulin blood product , autologous blood transfusion , give 5 month prior vaccination expect treat study Subject take non topical antiviral therapy activity herpesviruses . Subject immunosuppressive therapy Subject know suspect immune dysfunction cause medical condition , cause Subject history hypersensitivity reaction anaphylactoid reaction vaccine component , include gelatin neomycin Subject know active tuberculosis Subject significant underlying illness prevent completion study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>